Rucaparib
- Generic Name
- Rucaparib
- Brand Names
- Rubraca
- Drug Type
- Small Molecule
- Chemical Formula
- C19H18FN3O
- CAS Number
- 283173-50-2
- Unique Ingredient Identifier
- 8237F3U7EH
- Background
Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that la...
- Indication
Rucaparib is indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
...
- Associated Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC), Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer
- Associated Therapies
- Maintenance therapy
Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib
- First Posted Date
- 2016-12-08
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 6
- Registration Number
- NCT02986100
- Locations
- 🇭🇺
PRA Magyarország Kft., Budapest, Rottenbiller Utca 13, Hungary
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
- Conditions
- Interventions
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 405
- Registration Number
- NCT02975934
- Locations
- 🇺🇸
Urology Clinics of North Texas, Dallas, Texas, United States
🇺🇸Texas Oncology Cancer Center-Round Rock, Round Rock, Texas, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
- Conditions
- Interventions
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 277
- Registration Number
- NCT02952534
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇺🇸Atlanta Urological Group, Atlanta, Georgia, United States
A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-10-17
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 190
- Registration Number
- NCT02935634
- Locations
- 🇺🇸
Local Institution - 0001, Hackensack, New Jersey, United States
🇩🇪Local Institution - 0043, Leipzig, Germany
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
The Drug Rediscovery Protocol (DRUP Trial)
- Conditions
- Interventions
- Drug: PanitumumabDrug: OlaparibDrug: CrizotinibDrug: ErlotinibDrug: AlectinibDrug: Ipilimumab and nivolumabDrug: SunitinibDrug: Trastuzumab and Pertuzumab (combination treatment)Drug: Vemurafenib and Cobimetinib (combination treatment)Drug: NivolumabDrug: Dabrafenib and trametinibDrug: SelpercatinibDrug: TepotinibDrug: AbemaciclibDrug: ErdafitinibDrug: Atezolizumab and BevacizumabDrug: DacomitinibDrug: DabrafenibDrug: NilotinibDrug: TrametinibDrug: VismodegibDrug: RegorafenibDrug: AfatinibDrug: RibociclibDrug: LenvatinibDrug: PembrolizumabDrug: DurvalumabDrug: RucaparibDrug: AxitinibDrug: PalbociclibDrug: CabozantinibDrug: EntrectinibDrug: TalazoparibDrug: LorlatinibDrug: AlpelisibDrug: NiraparibDrug: Pemigatinib
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 1550
- Registration Number
- NCT02925234
- Locations
- 🇳🇱
Meander medisch centrum, Amersfoort, Netherlands
🇳🇱Netherlands Cancer Institute, Amsterdam, Netherlands
🇳🇱Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
- Conditions
- Interventions
- First Posted Date
- 2016-08-22
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 73
- Registration Number
- NCT02873962
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2016-08-04
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 349
- Registration Number
- NCT02855944
- Locations
- 🇵🇱
Bialostockie Centrum Onkologii im. Marii Sklodowskiej-Curie, Bialystok, Poland
🇺🇦Volyn Regional Oncology Dispensary, Lutsk, Ukraine
🇺🇦Sumy Regional Oncology Center, Sumy, Ukraine
Pharmacokinetic Drug-Drug Interaction Study of Rucaparib
- Conditions
- Interventions
- First Posted Date
- 2016-04-15
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 17
- Registration Number
- NCT02740712
- Locations
- 🇵🇱
BioVirtus Research Site, Kajetany, Mokra 7, Poland
🇵🇱Zachodniopomorskie Centrum Onkologii Centrum Innowacji, Szczecin, Poland
🇵🇱Med Polonia, Poznan, Poland
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2016-03-17
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 137
- Registration Number
- NCT02711137
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸Hematology - Oncology Associates of Treasure Coast, Port Saint Lucie, Florida, United States
🇺🇸The Methodist Hospital, Houston, Texas, United States
Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Target Recruit Count
- 924
- Registration Number
- NCT02678182
- Locations
- 🇬🇧
The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Sutton, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.